72 results
8-K
EX-99.1
ADAP
Adaptimmune Therapeutics Plc
6 Mar 24
Adaptimmune Reports Q4 /Full Year 2023 Financial Results and Business Updates
7:05am
, a decrease in share-based compensation expenses and a decrease in in-process research and development costs, which was mostly offset by a decrease … Therapeutics, Inc merger agreement and severance and other related costs for former TCR2 Therapeutics leadership, offset by a decrease in share-based
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
of Section 409A be subject to offset by any other amount unless otherwise permitted by Section 409A.
IN WITNESS WHEREOF, the parties hereto have executed
8-K
EX-99.1
hcnzml
8 Nov 23
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:37am
8-K
EX-99.1
z76kdbqoz0lfr4hn
9 Aug 23
Adaptimmune Reports Second Quarter Financial Results and Business Update
7:42am
8-K
EX-99.1
lcvbfadhyu8q8yw40m4
12 May 23
Adaptimmune Reports First Quarter Financial Results and Business Update
7:36am
424B3
b19ciduq32irkzt5
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
z6oxr6bviu
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4
no6x2je35ixjbfkog
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
8-K
EX-99.1
kfi9j374 7p527
8 Nov 22
Adaptimmune Reports Third-Quarter Financial Results and Business Update
7:42am
8-K
EX-99.1
4kozzxsh5rqh8f
4 Aug 22
Adaptimmune Reports Second-Quarter Financial Results and Business Update
7:36am
8-K
EX-99.1
cn3vo9k
14 Mar 22
Adaptimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update
8:06am